Polpharma Sa Pharmaceutical Works
Polpharma SA Pharmaceutical Works, commonly referred to as Polpharma, is a leading player in the pharmaceutical industry, headquartered in Poland (PL). Established in 1935, the company has grown to become one of the largest pharmaceutical manufacturers in Central and Eastern Europe, with significant operations across various regions. Polpharma focuses on the development, production, and distribution of generic and innovative medicines, particularly in therapeutic areas such as cardiology, oncology, and neurology. Its commitment to quality and accessibility sets it apart in a competitive market. The company has achieved notable milestones, including numerous international certifications and partnerships that enhance its global reach. With a robust portfolio of core products and a strong market position, Polpharma continues to contribute to healthcare advancements, making it a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Polpharma Sa Pharmaceutical Works's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Polpharma Sa Pharmaceutical Works's score of 18 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Polpharma Sa Pharmaceutical Works's reported carbon emissions
In 2023, Polpharma Sa Pharmaceutical Works reported total carbon emissions of approximately 123,858,000 kg CO2e. This figure includes 8,664,000 kg CO2e from Scope 1 emissions, which primarily arise from direct operations, and 51,193,000 kg CO2e from Scope 2 emissions, related to purchased electricity and steam. Notably, the company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. In 2022, the total emissions were about 161,663,000 kg CO2e, with Scope 1 emissions at 8,783,000 kg CO2e and Scope 2 emissions at 75,086,000 kg CO2e. The Scope 3 emissions for the same year were approximately 92,483,000 kg CO2e, which encompass indirect emissions from the supply chain and product use. The emissions data indicates a slight decrease in total emissions from 2022 to 2023, reflecting ongoing efforts to manage carbon output. However, without specific reduction targets or commitments, the long-term impact of these efforts remains uncertain. Polpharma's emissions intensity metrics, such as emissions per employee, suggest a focus on improving operational efficiency, but further details on strategic climate commitments are lacking.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 11,619,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 81,662,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 69,182,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Polpharma Sa Pharmaceutical Works is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
